| abstract |
The invention relates to an endothelial growth factor (VEGF) in which the alanine at AS position 111 is replaced by proline and the arginine at AS position 110 can be substituted by another amino acid. The invention also relates to derivatives of the inventive VEGF, nucleic acids, expression systems, medicaments, and the use of the VEGF mutants of the invention for treating chronic wounds. |